Adjuvant therapy of triple negative breast cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2010-01-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-010-0736-zPMID 20094772PMCID PMC3918886
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338

  2013cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Fragile histidine triad protein, WW domain‐containing oxidoreductase protein Wwox, and activator protein 2γ expression levels correlate with basal phenotype in breast cancer

  2009cited by this paper
• Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

  2009cited by this paper
• The Epothilones: How Pharmacology Relates to Clinical Utility

  2009cited by this paper
• The role of antiangiogenesis therapy: Bevacizumab and beyond

  2009cited by this paper
• Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.

  2009influential reference
• Patho-biological aspects of basal-like breast cancer

  2009cited by this paper
• RNA-Seq: a revolutionary tool for transcriptomics

  2009cited by this paper
• Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy

  2009influential reference
• Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

  2009cited by this paper
• Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.

  2009cited by this paper
• Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.

  2009cited by this paper
• Triple‐negative/basal‐like breast cancer: review

  2009cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Introducing molecular subtyping of breast cancer into the clinic?

  2009cited by this paper
• HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil

  2009cited by this paper
• Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA

  2008cited by this paper
• Platinum-based chemotherapy in triple-negative breast cancer.

  2008cited by this paper
• Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype

  2008cited by this paper
• Breast cancer subtypes and survival in patients with brain metastases

  2008cited by this paper
• Triple-Negative Breast Cancer: Risk Factors to Potential Targets

  2008cited by this paper
• Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

  2008cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• Therapeutic Strategies for Triple-Negative Breast Cancer

  2008cited by this paper
• Basal-like breast cancer: a critical review.

  2008influential reference
• Advances in Breast Cancer: Pathways to Personalized Medicine

  2008cited by this paper
• Basal carcinoma of the breast revisited: an old entity with new interpretations

  2008cited by this paper
• Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

  2008cited by this paper
• Understanding and treating triple-negative breast cancer.

  2008cited by this paper
• Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.

  2008cited by this paper
• Transcriptome analysis of the normal human mammary cell commitment and differentiation process.

  2008cited by this paper
• MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer.

  2008cited by this paper
• Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

  2008cited by this paper
• What is triple-negative breast cancer?

  2008cited by this paper
• Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

  2008cited by this paper
• Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer

  2008cited by this paper
• Expression of BRCA1 protein in breast cancer and its prognostic significance.

  2008cited by this paper
• A functional Notch–survivin gene signature in basal breast cancer

  2008influential reference
• Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

  2008cited by this paper
• Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?

  2008cited by this paper
• TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer

  2008cited by this paper
• N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer

  2008cited by this paper
• Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology

  2007cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper
• Triple negative tumours: a critical review

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• The role of BRCA1 in the cellular response to chemotherapy.

  2004cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Second malignancies in melanoma patients in Thuringia

  2000cited by this paper

• Aptamer-directed siRNA delivery systems for triple-negative breast cancer therapy.

  2025cites this paper
• mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation

  2024cites this paper
• Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer

  2023cites this paper
• Impact of digitization on green economic recovery: an empirical evidence from China

  2023cites this paper
• Assessing the impacts of Covid-19 on stock exchange, gold prices, and financial markets: Fresh evidences from econometric analysis

  2023cites this paper
• Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

  2022cites this paper
• Economic Analysis and Policy

  2022cites this paper
• Role of fiscal and monetary policies for economic recovery in China

  2022cites this paper
• Regulation of programmed death ligand 1 (PD‐L1) expression by TNF‐related apoptosis‐inducing ligand (TRAIL) in triple‐negative breast cancer cells

  2022cites this paper
• The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer

  2022cites this paper
• Measuring the combining effects of financial stability and climate risk for green economic recovery

  2022cites this paper
• Targeting PP2A for cancer therapeutic modulation

  2022cites this paper
• Targeting PP2A inhibits the growth of triple-negative breast cancer cells

  2020cites this paper
• Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer

  2019cites this paper
• A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

  2019cites this paper
• Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy

  2018cites this paper
• Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy

  2018cites this paper
• Calmodulin antagonist enhances DR5‐mediated apoptotic signaling in TRA‐8 resistant triple negative breast cancer cells

  2018cites this paper
• Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance

  2018cites this paper
• Triple-Negative Breast Cancer

  2018cites this paper
• A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway.

  2018cites this paper
• Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes

  2017cites this paper
• Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience

  2017cites this paper
• ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells

  2017cites this paper
• Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes.

  2016cites this paper
• A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer

  2016cites this paper
• Clinical effects of laser immunotherapy on metastatic cancer patients

  2016cites this paper
• Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.

  2015cites this paper
• Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer.

  2015cites this paper
• Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study.

  2015cites this paper
• Subtyping of breast cancer using reverse phase protein arrays

  2014cites this paper
• Companion Diagnostics and Cancer Biomarkers miR-185 Suppresses Tumor Proliferation by Directly Targeting E 2 F 6 and DNMT 1 and Indirectly Upregulating BRCA 1 in Triple-Negative Breast Cancer

  2014cites this paper
• miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer

  2014cites this paper
• Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase II clinical trial

  2014cites this paper
• Distribución fenotípica del carcinoma de mama en Venezuela

  2013cites this paper
• Adjunctive imprint cytology of core needle biopsy specimens improved diagnostic accuracy for breast cancer

  2013cites this paper
• Deregulated Expression of ANXA1 in Human High-Grade Breast Cancers

  2013cites this paper
• There Is No Association between MicroRNA Gene Polymorphisms and Risk of Triple Negative Breast Cancer in a Chinese Han Population

  2013cites this paper
• RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

  2012cites this paper
• Triple negative breast cancer: a retrospective study of Hispanics residing in Puerto Rico.

  2012cites this paper
• Adjuvant treatments for triple-negative breast cancers.

  2012cites this paper
• Effect of anti-DR5 and chemotherapy on basal-like breast cancer

  2012cites this paper
• Predictive Biomarkers and Personalized Medicine RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

  2012cites this paper
• Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience.

  2012cites this paper
• Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs

  2012cites this paper
• FZD7 in Triple Negative Breast Cancer Cells

  2011cites this paper
• Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.

  2011cites this paper
• Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer.

  2011cites this paper
• Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients

  2011cites this paper
• Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

  2011cites this paper
• CIDE-3 interacts with lipopolysaccharide-induced tumor necrosis factor, and overexpression increases apoptosis in hepatocellular carcinoma

  2011cites this paper
• FZD7 has a critical role in cell proliferation in triple negative breast cancer

  2011cites this paper
• Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome.

  2011cites this paper
• Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates

  2010cites this paper
• Putting the brakes on breast cancer: therapeutic opportunities to bring cancer stem cells and the tumor microenvironment to a screeching halt.

  2010cites this paper
• Treatment of triple negative breast cancer (TNBC): current options and future perspectives.

  2010cites this paper
• Reinventing Diagnostics for Personalized Therapy in Oncology

  2010cites this paper
• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

  2009cites this paper